已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature

医学 胰腺癌 免疫疗法 肿瘤科 腺癌 癌症 内科学 化疗 进行性疾病 癌症研究
作者
Lijie Qiu,Chen Liu,Heping Li
出处
期刊:Anti-Cancer Drugs [Ovid Technologies (Wolters Kluwer)]
被引量:1
标识
DOI:10.1097/cad.0000000000001546
摘要

Pancreatic cancer is a highly malignant tumor, and most patients are diagnosed at an advanced stage. Unfortunately, due to the immunosuppressive tumor microenvironment of pancreatic cancer, the benefits of immunotherapy for patients with advanced pancreatic cancer are still unclear. Here, we present two cases of advanced pancreatic cancer being controlled by immunotherapy, with pathological diagnoses of ductal adenocarcinoma and acinar cell carcinoma, respectively. Next-generation sequencing (NGS) of both patients is high tumor mutation burden (tumor mutation burden—High) and microsatellite stable. The patient with pancreatic ductal adenocarcinoma was diagnosed as a locally advanced disease (stage III). She received irreversible electroporation, used the programmed death receptor-1 (PD-1) inhibitor (pembrolizumab) combined with chemotherapy (S-1), and then used only the PD-1 inhibitor as a maintenance treatment. As a result, the patient’s lesion was significantly reduced, with a partial response time of up to 31 months. The patient with acinar cell carcinoma was diagnosed as a metastatic disease (stage IV), next-generation sequencing revealed mutations in SMAD4 and KMT2D, and two chemotherapy regimens were used unsuccessfully. Then, the combination of chemotherapy with PD-1 (tislelizumab) and vascular endothelial growth factor/vascular endothelial growth factor receptor (anlotinib) inhibitors were used, and the lesions of the patient were significantly reduced, and the progression-free survival after immunotherapy was 19 months. In advanced pancreatic cancer, a prognosis of this magnitude is rare. Our cases reveal the potential of immunotherapy as a cornerstone treatment in the management of advanced pancreatic cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
故意的如冬完成签到,获得积分10
刚刚
冷静的莞完成签到 ,获得积分10
2秒前
魁梧的鸿煊完成签到 ,获得积分10
2秒前
zsyf完成签到,获得积分10
2秒前
。。完成签到 ,获得积分10
3秒前
迅速的念芹完成签到 ,获得积分10
4秒前
4秒前
zuhangzhao完成签到 ,获得积分10
4秒前
尊敬柏柳完成签到 ,获得积分10
6秒前
13654135090完成签到,获得积分10
7秒前
黄憨憨发布了新的文献求助10
8秒前
Hasee完成签到 ,获得积分10
9秒前
ccc完成签到 ,获得积分10
10秒前
ZeKaWa发布了新的文献求助10
10秒前
10秒前
糟糕的铁身给YI的求助进行了留言
11秒前
科研dog完成签到,获得积分10
12秒前
淡淡菠萝完成签到 ,获得积分10
12秒前
12秒前
czy完成签到 ,获得积分10
12秒前
鹏程万里发布了新的文献求助10
13秒前
kingway完成签到,获得积分20
14秒前
marchon完成签到 ,获得积分10
14秒前
哈哈完成签到 ,获得积分10
15秒前
re发布了新的文献求助10
17秒前
欣欣子完成签到 ,获得积分10
18秒前
18秒前
20秒前
大碗完成签到 ,获得积分10
21秒前
21秒前
sakiko完成签到,获得积分10
22秒前
小凯完成签到 ,获得积分10
22秒前
25秒前
糟糕的铁身给YI的求助进行了留言
25秒前
风中的丝袜完成签到,获得积分10
26秒前
逃离地球完成签到 ,获得积分10
26秒前
baiyeok发布了新的文献求助10
26秒前
rr完成签到,获得积分10
26秒前
曹文鹏完成签到 ,获得积分10
26秒前
28秒前
高分求助中
Rock-Forming Minerals, Volume 3C, Sheet Silicates: Clay Minerals 2000
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
The Healthy Socialist Life in Maoist China 600
The Vladimirov Diaries [by Peter Vladimirov] 600
Data Structures and Algorithms in Java 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3268485
求助须知:如何正确求助?哪些是违规求助? 2908048
关于积分的说明 8344158
捐赠科研通 2578313
什么是DOI,文献DOI怎么找? 1401979
科研通“疑难数据库(出版商)”最低求助积分说明 655240
邀请新用户注册赠送积分活动 634359